Related Experiment Video
Updated: May 4, 2026
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
The efficacy of dexamethasone on reduction in the reoperation rate of chronic subdural hematoma--the DRESH study:
Stephan Emich1, Bernd Richling, Marc R McCoy
1Christian Doppler Klinik, PMU Salzburg, Universitätsklinik für Neurochirurgie, Ignaz Harrer Str, 79, 5020 Salzburg, Austria. s.emich@salk.at.
Insights
This study investigates dexamethasone to prevent chronic subdural hematoma (cSDH) recurrence after surgery. Dexamethasone may reduce reoperation rates, offering a potential new treatment for this common neurosurgical condition.
Area of Science:
- Neurosurgery
- Pharmacology
Background:
- Chronic subdural hematoma (cSDH) is a frequent neurosurgical condition with recurrence rates up to 30% despite surgical intervention.
- The role of glucocorticoids, like dexamethasone, in cSDH management remains controversial due to limited evidence.
- Inflammation is implicated in cSDH, suggesting dexamethasone could be beneficial in treatment protocols.
Purpose of the Study:
- To evaluate the efficacy of dexamethasone in reducing the reoperation rate for chronic subdural hematoma.
- To determine if a short-term dexamethasone regimen can prevent cSDH relapses after surgical evacuation.
Main Methods:
- A double-blind, randomized, placebo-controlled trial involving 820 patients aged 25+ undergoing surgery for cSDH.
- Patients received either dexamethasone (16-16-12-12-8-4 mg/d) or placebo (maltodextrin) for the first 48 hours post-surgery.
- The primary endpoint was reoperation within 12 weeks, with a 5% type I error and 20% type II error rate.
Main Results:
- Results are pending as this abstract outlines the study design and objectives.
- The study is designed to provide definitive data on dexamethasone's impact on cSDH recurrence.
Conclusions:
- This trial aims to ascertain if a 6-day dexamethasone administration is a safe and effective method for preventing recurrence in surgically treated cSDH patients.
Background:
Chronic subdural hematoma (cSDH) is a common neurosurgical disease. It is often considered to be a rather benign entity. In spite of well established surgical procedures cSDH is complicated by a recurrence rate up to 30%. Since glucocorticoids have been used for treatment of cSDH in 1962 their role is still discussed controversially in lack of evident data. On the basis of the ascertained inflammation cycle in cSDH dexamethasone will be an ideal substance for a short lasting, concomitant treatment protocol.
Objective:
to test the efficacy of dexamethasone on reduction inthe reoperation rate of cSDH.
Methods/Design:
The study is designed as a double-blind randomized placebo-controlled trial 820 patients who are operated for cSDH and from the age of 25 years are included after obtaining informed consent. They are randomized for administration of dexamethasone (16-16-12-12-8-4 mg/d) or placebo (maltodextrin) during the first 48 hours after surgery. The type I error is 5% and the type II error is 20%. The primary endpoint is the reoperation within 12 weeks postoperative.
Discussion:
This study tests whether dexamethasone administered over 6 days is a safe and potent agent in relapse prevention for evacuated cSDH.
Trial Registration:
EudraCT 201100354442.
